Daniel L. Flynn
Publications by Year
Research Areas
Chemical Synthesis and Analysis, Synthetic Organic Chemistry Methods, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Melanoma and MAPK Pathways
Most-Cited Works
- → Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers(2015)305 cited
- → Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants(2019)275 cited
- → A mild two-step method for the hydrolysis of lactams and secondary amides(1983)272 cited
- → Chemical Library Purification Strategies Based on Principles of Complementary Molecular Reactivity and Molecular Recognition(1997)211 cited
- → Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036(2011)204 cited
- → The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors(2017)163 cited
- → The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile(2011)119 cited
- → Inhibition of human neutrophil 5-lipoxygenase activity by gingerdione, shogaol, capsaicin and related pungent compounds(1986)115 cited
- → Three novel patient‐derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors(2012)111 cited
- → Inhibition of 5-hydroxy-eicosatetraenoic acid (5-HETE) formation in intact human neutrophils by naturally-occurring diarylheptanoids: inhibitory activities of curcuminoids and yakuchinones(1986)107 cited